Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,034 across all filing types
Latest filing 2023-05-25 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges referencing a transcript of an earnings call held on May 22, 2023, for the fourth quarter and year ended March 31, 2023. It states that the transcript has been uploaded on the company's website and requests the exchanges to take it on record. The document itself does not contain the transcript but is an announcement about the transcript's availability. The document length is short (1569 characters), and it primarily serves as a notification rather than the full transcript text. According to the rules, announcements about transcripts or reports being available on the website should be classified as Regulatory Filings (RNS) rather than Call Transcript (CT).
2023-05-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges confirming the uploading of the audio recording of the Q4 FY 2022-23 Earnings Call on the company's website. It references the SEBI Listing Obligations and Disclosure Requirements and provides a link to the earnings call recording. The document does not contain the earnings call transcript itself, nor does it provide financial data or analysis. It is essentially an announcement that the earnings call audio has been made available. The document length is short (1523 characters), and it serves as a notification rather than the full transcript or report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and confirmations that do not fit other categories.
2023-05-22 English
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a disclosure of Related Party Transactions for the half year ended 31st March 2023, submitted pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It contains detailed transactional data between the listed entity and its related parties for a specific half-year period, including values of transactions and balances. This type of disclosure is a regulatory filing related to compliance with listing obligations rather than a full financial report or earnings release. It is not an Annual Report, Interim Report, or Earnings Release, but a specific regulatory disclosure. Given the nature and detail, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous compliance filings that do not fit other categories.
2023-05-19 English
Change in Management
Board/Management Information Classification · 100% confidence The document is a formal announcement dated May 19, 2023, regarding the outcome of a Board Meeting of Glenmark Pharmaceuticals Limited. It details the re-appointment of an Executive Director & Global Chief Financial Officer, Mr. V.S. Mani, for a further period of 3 years. The document includes references to SEBI regulations and circulars, and provides a brief profile of the director. There is no financial data, earnings information, or detailed report content. The document is clearly an announcement about a change in senior management, specifically a re-appointment at the board/executive level. Therefore, it fits the category of Board/Management Information (MANG).
2023-05-19 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation: Q4 & FY23' and is dated May 19, 2023. It contains detailed financial data including quarterly and full fiscal year revenues, EBITDA, R&D expenses, profit/loss figures, segmental revenue breakdowns, and balance sheet highlights. The content includes forward-looking statements, strategic business information, and operational highlights. The document is approximately 15,000 characters long, indicating it is a full presentation rather than a brief announcement. The presence of detailed financial metrics and strategic commentary aligns with the characteristics of an Investor Presentation. There is no indication that this is a regulatory filing, earnings release, or annual report. Therefore, the document fits best under the category 'Investor Presentation' (IP).
2023-05-19 English
Updates
Regulatory Filings
2023-05-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.